HomeCompareSPHD vs BSX

SPHD vs BSX: Dividend Comparison 2026

SPHD yields 4.33% · BSX yields 3.18%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SPHD wins by $6.3K in total portfolio value
10 years
SPHD
SPHD
● Live price
4.33%
Share price
$49.34
Annual div
$2.14
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.5K
Annual income
$571.32
Full SPHD calculator →
BSX
BSX
● Live price
3.18%
Share price
$62.93
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.2K
Annual income
$0.32
Full BSX calculator →

Portfolio growth — SPHD vs BSX

📍 SPHD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSPHDBSX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SPHD + BSX cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SPHD pays
BSX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SPHD
Annual income on $10K today (after 15% tax)
$367.92/yr
After 10yr DRIP, annual income (after tax)
$485.62/yr
BSX
Annual income on $10K today (after 15% tax)
$270.14/yr
After 10yr DRIP, annual income (after tax)
$0.27/yr
At 15% tax rate, SPHD beats the other by $485.35/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SPHD + BSX for your $10,000?

SPHD: 50%BSX: 50%
100% BSX50/50100% SPHD
Portfolio after 10yr
$23.4K
Annual income
$285.82/yr
Blended yield
1.22%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BSX right now

SPHD
No analyst data
BSX
Analyst Ratings
2
Strong
38
Buy
3
Hold
Consensus: Buy
Price Target
$108.35
+72.2% upside vs current
Range: $94.00 — $130.00
Altman Z
3.9
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SPHD buys
0
BSX buys
6
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$BSX▲ Buy$1,001 - $15,0002026-02-10
Gilbert Cisneros🏢 House$BSX▲ Buy$1,001 - $15,0002026-01-30
Markwayne Mullin🏛 Senate$BSX▲ Buy$15,001 - $50,0002025-12-29
Markwayne Mullin🏛 Senate$BSX▲ Buy$15,001 - $50,0002025-12-29
Gilbert Cisneros🏢 House$BSX▼ Sell$1,001 - $15,0002025-12-24
John Boozman🏛 Senate$BSX▼ Sell$1,001 - $15,0002025-12-17
John Boozman🏛 Senate$BSX▼ Sell$1,001 - $15,0002025-12-17
Gilbert Cisneros🏢 House$BSX▲ Buy$1,001 - $15,0002025-11-18
Kevin Hern🏢 House$BSX▼ Sell$15,001 - $50,0002025-10-28
Gilbert Cisneros🏢 House$BSX▲ Buy$1,001 - $15,0002025-10-17
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSPHDBSX
Forward yield4.33%3.18%
Annual dividend / share$2.14$2.00
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-50%
Portfolio after 10y$26.5K$20.2K
Annual income after 10y$571.32$0.32
Total dividends collected$5.1K$321.00
Payment frequencyquarterlyquarterly
SectorETFHealthcare

Year-by-year: SPHD vs BSX ($10,000, DRIP)

YearSPHD PortfolioSPHD Income/yrBSX PortfolioBSX Income/yrGap
1← crossover$11,133$432.85$10,859$158.91+$274.00SPHD
2$12,363$450.36$11,700$80.63+$663.00SPHD
3$13,695$467.39$12,559$40.60+$1.1KSPHD
4$15,138$483.90$13,459$20.36+$1.7KSPHD
5$16,697$499.88$14,411$10.20+$2.3KSPHD
6$18,382$515.31$15,425$5.10+$3.0KSPHD
7$20,198$530.17$16,507$2.55+$3.7KSPHD
8$22,157$544.46$17,664$1.28+$4.5KSPHD
9$24,266$558.18$18,901$0.64+$5.4KSPHD
10$26,536$571.32$20,225$0.32+$6.3KSPHD

SPHD vs BSX: Complete Analysis 2026

SPHDETF

The Invesco S&P 500 High Dividend Low Volatility ETF (Fund) is based on the S&P 500 Low Volatility High Dividend Index (Index). The Fund will invest at least 90% of its total assets in common stocks that comprise the Index. Standard & Poor's compiles, maintains and calculates the Index, which is composed of 50 securities traded on the S&P 500 Index that historically have provided high dividend yields and low volatility. The Fund and the Index are rebalanced and reconstituted semi-annually, in January and July.

Full SPHD Calculator →

BSXHealthcare

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Full BSX Calculator →
📬

Get this SPHD vs BSX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SPHD vs SCHDSPHD vs JEPISPHD vs OSPHD vs KOSPHD vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.